{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:11:48Z","timestamp":1791684708164,"version":"4.3.4"},"reference-count":216,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 NS082265"],"award-info":[{"award-number":["RO1 NS082265"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 NS115139"],"award-info":[{"award-number":["RO1 NS115139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG062418"],"award-info":[{"award-number":["U19 AG062418"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014989","name":"Chan Zuckerberg Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014989","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006458","name":"Children's Hospital of Philadelphia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuron"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.neuron.2023.03.021","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T10:41:34Z","timestamp":1680777694000},"page":"1531-1546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Cognitive heterogeneity in Parkinson\u2019s disease: A mechanistic view"],"prefix":"10.1016","volume":"111","author":[{"given":"Marc","family":"Carceles-Cordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice S.","family":"Chen-Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuron.2023.03.021_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jnnp.2010.232678","article-title":"Dementia in Parkinson\u2019s disease: a 20-year neuropsychological study (Sydney Multicentre Study)","volume":"82","author":"Reid","year":"2011","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuron.2023.03.021_bib3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/brain\/awm111","article-title":"Evolution of cognitive dysfunction in an incident Parkinson\u2019s disease cohort","volume":"130","author":"Williams-Gray","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1212\/WNL.0000000000002001","article-title":"Longitudinal study of normal cognition in Parkinson disease","volume":"85","author":"Pigott","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/gps.3970","article-title":"Quality of life, health status and caregiver burden in Parkinson\u2019s disease: relationship to executive functioning","volume":"29","author":"Kudlicka","year":"2014","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuron.2023.03.021_bib6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/mds.23661","article-title":"The economic impact of cognitive impairment in Parkinson\u2019s disease","volume":"26","author":"Vossius","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/0891988704267470","article-title":"Are Parkinson\u2019s disease with dementia and dementia with Lewy bodies the same entity?","volume":"17","author":"Aarsland","year":"2004","journal-title":"J.\u00a0Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J.\u00a0Parkinsons Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/brain\/awh067","article-title":"The cognitive ability of an incident cohort of Parkinson\u2019s patients in the UK. The CamPaIGN study","volume":"127","author":"Foltynie","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study","volume":"60","author":"Aarsland","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/mds.27135","article-title":"Cognitive changes in prodromal Parkinson\u2019s disease: a review","volume":"32","author":"Fengler","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaneurol.2017.2248","article-title":"Association between poor cognitive functioning and risk of incident parkinsonism: the Rotterdam Study","volume":"74","author":"Darweesh","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/brain\/aww291","article-title":"Trajectories of prediagnostic functioning in Parkinson\u2019s disease","volume":"140","author":"Darweesh","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/mds.26373","article-title":"Cognition in individuals at risk for Parkinson\u2019s: Parkinson associated risk syndrome (PARS) study findings","volume":"31","author":"Chahine","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib15","first-page":"619","article-title":"Longitudinal study of cognitive function in idiopathic REM sleep behavior disorder","volume":"34","author":"Fantini","year":"2011","journal-title":"Sleep"},{"key":"10.1016\/j.neuron.2023.03.021_bib16","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S1474-4422(10)70212-X","article-title":"Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson\u2019s disease","volume":"9","author":"Kehagia","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1037\/0894-4105.11.1.44","article-title":"Visuospatial dysfunction and problem solving in Parkinson\u2019s disease","volume":"11","author":"Cronin-Golomb","year":"1997","journal-title":"Neuropsychology"},{"key":"10.1016\/j.neuron.2023.03.021_bib18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0028-3932(02)00257-9","article-title":"Using executive heterogeneity to explore the nature of working memory deficits in Parkinson\u2019s disease","volume":"41","author":"Lewis","year":"2003","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuron.2023.03.021_bib19","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.0b013e3181f39d0e","article-title":"Mild cognitive impairment in Parkinson\u2019s disease: a multicenter pooled analysis","volume":"75","author":"Aarsland","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib20","first-page":"2713","article-title":"Predictors of cognitive impairment in Parkinson\u2019s disease: a\u00a0systematic review and meta-analysis of prospective cohort studies","volume":"268","author":"Guo","year":"2021","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force Guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/mds.27233","article-title":"Global scales for cognitive screening in Parkinson\u2019s disease: critique and recommendations","volume":"33","author":"Skorvanek","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib24","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/mds.110","article-title":"Detecting mild cognitive deficits in Parkinson\u2019s disease: comparison of neuropsychological tests","volume":"33","author":"Hoogland","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","article-title":"APOE \u03b54 increases risk for dementia in pure synucleinopathies","volume":"70","author":"Tsuang","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","article-title":"Are dementia with Lewy bodies and Parkinson\u2019s disease dementia the same disease?","volume":"16","author":"Jellinger","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/ana.24664","article-title":"\u03b1-Synuclein genetic variability: a biomarker for dementia in Parkinson disease","volume":"79","author":"Guella","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib29","doi-asserted-by":"crossref","first-page":"e0150621","DOI":"10.1371\/journal.pone.0150621","article-title":"Associations between anticholinergic burden and adverse health outcomes in Parkinson disease","volume":"11","author":"Crispo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neuron.2023.03.021_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","article-title":"Use of drugs with anticholinergic effect and impact on cognition in Parkinson\u2019s disease: a cohort study","volume":"81","author":"Ehrt","year":"2010","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuron.2023.03.021_bib31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11065-020-09473-1","article-title":"Sleep disorders and cognitive dysfunctions in Parkinson\u2019s disease: a meta-analytic study","volume":"31","author":"Maggi","year":"2021","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.neuron.2023.03.021_bib32","first-page":"CD006504","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease","volume":"2012","author":"Rolinski","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuron.2023.03.021_bib33","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"Emre","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Emre","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib35","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/mds.22495","article-title":"Randomized controlled trial of memantine in dementia associated with Parkinson\u2019s disease","volume":"24","author":"Leroi","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/mds.26617","article-title":"Rasagiline for mild cognitive impairment in Parkinson\u2019s disease: a placebo-controlled trial","volume":"31","author":"Weintraub","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib38","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mdc3.12455","article-title":"A randomized clinical trial of atomoxetine for mild cognitive impairment in Parkinson\u2019s disease","volume":"4","author":"Hinson","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neuron.2023.03.021_bib39","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/mds.26236","article-title":"Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo\u2212controlled study","volume":"30","author":"Mamikonyan","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/mds.28879","article-title":"Safety and efficacy of mevidalen in Lewy body dementia: a phase 2, randomized, placebo-controlled trial","volume":"37","author":"Biglan","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib41","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/mds.28020","article-title":"A phase 2a trial investigating the safety and tolerability of the novel cortical enhancer IRL752 in Parkinson\u2019s disease dementia","volume":"35","author":"Svenningsson","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41531-018-0055-3","article-title":"Cognitive impairment in Parkinson\u2019s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health","volume":"4","author":"Goldman","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib43","first-page":"1222","article-title":"Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials","volume":"268","author":"Dauwan","year":"2021","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib44","first-page":"CD011961","article-title":"Cognitive training interventions for dementia and mild cognitive impairment in Parkinson\u2019s disease","volume":"2","author":"Orgeta","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuron.2023.03.021_bib45","doi-asserted-by":"crossref","first-page":"e068718","DOI":"10.1136\/bmj-2021-068718","article-title":"Management of psychiatric and cognitive complications in Parkinson\u2019s disease","volume":"379","author":"Weintraub","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.neuron.2023.03.021_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","article-title":"Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study","volume":"16","author":"Schrag","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib47","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/brain\/awz030","article-title":"Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study","volume":"142","author":"Postuma","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib48","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","article-title":"Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria","volume":"8","author":"Dickson","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib49","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2023.03.021_bib50","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.neuron.2023.03.021_bib51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"\u03b1-Synuclein locus triplication causes Parkinson\u2019s disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuron.2023.03.021_bib52","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","article-title":"Increased expression of \u03b1-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis","volume":"65","author":"Nemani","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuron.2023.03.021_bib53","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"\u03b1-Synuclein promotes SNARE-complex assembly in\u00a0vivo and in\u00a0vitro","volume":"329","author":"Burr\u00e9","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuron.2023.03.021_bib54","doi-asserted-by":"crossref","first-page":"E4274","DOI":"10.1073\/pnas.1416598111","article-title":"\u03b1-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation","volume":"111","author":"Burr\u00e9","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2023.03.021_bib55","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"\u03b1-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuron.2023.03.021_bib56","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuron.2023.03.021_bib57","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00401-011-0815-1","article-title":"Changes in the solubility and phosphorylation of \u03b1-synuclein over the course of Parkinson\u2019s disease","volume":"121","author":"Zhou","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuron.2023.03.021_bib59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneurol.2017.26","article-title":"Multiple system atrophy: insights into a rare and debilitating movement disorder","volume":"13","author":"Krismer","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/mds.25880","article-title":"Cognitive impairment in multiple system atrophy: a position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group","volume":"29","author":"Stankovic","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib61","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3390\/jpm11090834","article-title":"Are Parkinson\u2019s disease patients the ideal preclinical population for Alzheimer\u2019s disease therapeutics?","volume":"11","author":"Tropea","year":"2021","journal-title":"J.\u00a0Pers. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib62","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of \u03b1-synuclein and A\u03b2 in Parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib63","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/acn3.51482","article-title":"Quantifying regional \u03b1 -synuclein, amyloid \u03b2, and tau accumulation in Lewy body dementia","volume":"9","author":"Miller","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib64","first-page":"1234","article-title":"Neuropathology of dementia in patients with Parkinson\u2019s disease: a systematic review of autopsy studies","volume":"90","author":"Smith","year":"2019","journal-title":"J.\u00a0Neurol. Neurosurg.Psychiatry"},{"key":"10.1016\/j.neuron.2023.03.021_bib65","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.parkreldis.2022.05.024","article-title":"Are there morphological differences between Parkinson\u2019s disease-dementia and dementia with Lewy bodies?","volume":"100","author":"Jellinger","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib67","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/NEN.0000000000000018","article-title":"Confluence of \u03b1-synuclein, tau, and\u00a0\u03b2-amyloid pathologies in dementia with Lewy bodies","volume":"72","author":"Colom-Cadena","year":"2013","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ana.25392","article-title":"Cognitive and pathological influences of tau pathology in Lewy body disorders","volume":"85","author":"Coughlin","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib69","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1082324","article-title":"Initiation and synergistic fibrillization of tau and alpha-synuclein","volume":"300","author":"Giasson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuron.2023.03.021_bib70","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192193","article-title":"\u03b1-Synuclein modulates tau spreading in mouse brains","volume":"218","author":"Bassil","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib71","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3233\/JAD-201187","article-title":"Cognition at each stage of lewy body disease with co-occurring Alzheimer\u2019s disease pathology","volume":"80","author":"Ryman","year":"2021","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib72","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/brain\/aws234","article-title":"Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies","volume":"135","author":"Schneider","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson\u2019s disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuron.2023.03.021_bib74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2009.08.007","article-title":"A timeline for Parkinson\u2019s disease","volume":"16","author":"Hawkes","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib75","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/01.WNL.0000158422.41380.82","article-title":"Cognitive status correlates with neuropathologic stage in Parkinson disease","volume":"64","author":"Braak","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib76","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/WNL.54.10.1916","article-title":"Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson\u2019s disease","volume":"54","author":"Hurtig","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib77","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2990.2007.00874.x","article-title":"Parkinson\u2019s disease: a dual-hit hypothesis","volume":"33","author":"Hawkes","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neuron.2023.03.021_bib78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0306-4522(91)90163-I","article-title":"Transneuronal transport of herpes simplex virus from the cervical vagus to brain neurons with axonal inputs to central vagal sensory nuclei in the rat","volume":"42","author":"Blessing","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuron.2023.03.021_bib79","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/BF00294234","article-title":"Parkinson\u2019s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system","volume":"79","author":"Wakabayashi","year":"1990","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib80","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00687767","article-title":"Parkinson\u2019s disease: the presence of Lewy bodies in Auerbach\u2019s and Meissner\u2019s plexuses","volume":"76","author":"Wakabayashi","year":"1988","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib81","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","article-title":"Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach\u2019s plexuses in cases staged for Parkinson\u2019s disease-related brain pathology","volume":"396","author":"Braak","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuron.2023.03.021_bib82","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00401-010-0665-2","article-title":"Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson\u2019s disease","volume":"119","author":"Del Tredici","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib83","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1038\/s41598-020-63412-x","article-title":"\u03b1-Synuclein inclusions are abundant in non-neuronal cells in the anterior olfactory nucleus of the Parkinson\u2019s disease olfactory bulb","volume":"10","author":"Stevenson","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuron.2023.03.021_bib84","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mds.870100309","article-title":"The anterior olfactory nucleus in Parkinson\u2019s disease","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrneurol.2010.52","article-title":"Molecular and clinical prodrome of Parkinson disease: implications for treatment","volume":"6","author":"Schapira","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib86","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson\u2019s disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib87","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.27802","article-title":"Update of the MDS research criteria for prodromal Parkinson's disease","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib88","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/jnnp-2015-311680","article-title":"Constipation preceding Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"87","author":"Adams-Carr","year":"2016","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuron.2023.03.021_bib89","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib90","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib91","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of \u03b1-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2023.03.021_bib92","doi-asserted-by":"crossref","first-page":"20051","DOI":"10.1073\/pnas.0908005106","article-title":"Exogenous \u03b1-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells","volume":"106","author":"Luk","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2023.03.021_bib93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.neuron.2023.03.021_bib94","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuron.2023.03.021_bib95","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1084\/jem.20112457","article-title":"Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in\u00a0mice","volume":"209","author":"Luk","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib96","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.neurobiolaging.2011.06.022","article-title":"Prion-like acceleration of a synucleinopathy in a transgenic mouse model","volume":"33","author":"Mougenot","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuron.2023.03.021_bib97","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/brain\/awt037","article-title":"Prion-like spreading of pathological \u03b1-synuclein in brain","volume":"136","author":"Masuda-Suzukake","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib98","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41593-019-0457-5","article-title":"Spread of \u03b1-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis","volume":"22","author":"Henderson","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuron.2023.03.021_bib99","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nbd.2015.06.003","article-title":"Intrastriatal injection of pre-formed mouse \u03b1-synuclein fibrils into rats triggers \u03b1-synuclein pathology and bilateral nigrostriatal degeneration","volume":"82","author":"Paumier","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib100","doi-asserted-by":"crossref","first-page":"104623","DOI":"10.1016\/j.nbd.2019.104623","article-title":"Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: involvement of retrograde and anterograde axonal propagation","volume":"134","author":"Mezias","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib101","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40478-017-0413-0","article-title":"Propagation of pathological \u03b1-synuclein in marmoset brain","volume":"5","author":"Shimozawa","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuron.2023.03.021_bib102","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fnana.2014.00159","article-title":"Alpha-synuclein spreading in Parkinson\u2019s disease","volume":"8","author":"Recasens","year":"2014","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuron.2023.03.021_bib103","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","article-title":"Cellular milieu imparts distinct pathological \u03b1-synuclein strains in \u03b1-synucleinopathies","volume":"557","author":"Peng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2023.03.021_bib104","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s40478-021-01288-2","article-title":"Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in\u00a0vitro","volume":"9","author":"Marotta","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuron.2023.03.021_bib105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ana.24066","article-title":"Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys","volume":"75","author":"Recasens","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuron.2023.03.021_bib107","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-019-02040-w","article-title":"Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats","volume":"138","author":"Van Den Berge","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib108","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.nbd.2018.01.008","article-title":"Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology","volume":"112","author":"Manfredsson","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13024-018-0257-5","article-title":"Inoculation of \u03b1-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve","volume":"13","author":"Uemura","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuron.2023.03.021_bib110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: a focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuron.2023.03.021_bib111","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41582-020-0333-7","article-title":"Protein transmission in neurodegenerative disease","volume":"16","author":"Peng","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib112","doi-asserted-by":"crossref","first-page":"12571","DOI":"10.1073\/pnas.0906759106","article-title":"Is Parkinson\u2019s disease a prion disorder?","volume":"106","author":"Olanow","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2023.03.021_bib113","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3858\/emm.2011.43.4.026","article-title":"Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers","volume":"43","author":"Lee","year":"2011","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib114","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1471-4159.2010.06695.x","article-title":"Non-classical exocytosis of \u03b1-synuclein is sensitive to folding states and promoted under stress conditions","volume":"113","author":"Jang","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuron.2023.03.021_bib115","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bpa.12370","article-title":"Alpha-synuclein as a biomarker for Parkinson\u2019s disease","volume":"26","author":"Atik","year":"2016","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib116","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1096\/fj.03-0098fje","article-title":"\u03b1-Synuclein implicated in Parkinson\u2019s disease is present in extracellular biological fluids, including human plasma","volume":"17","author":"El-Agnaf","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.neuron.2023.03.021_bib117","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/cells10020375","article-title":"Alpha-synuclein: mechanisms of release and pathology progression in synucleinopathies","volume":"10","author":"Br\u00e1s","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neuron.2023.03.021_bib118","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1096\/fj.10-164624","article-title":"Heat-shock protein 70 modulates toxic extracellular \u03b1-synuclein oligomers and rescues trans-synaptic toxicity","volume":"25","author":"Danzer","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.neuron.2023.03.021_bib119","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.nbd.2011.01.029","article-title":"Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission","volume":"42","author":"Alvarez-Erviti","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40478-017-0445-5","article-title":"Brain-derived exosomes from dementia with Lewy bodies propagate \u03b1-synuclein pathology","volume":"5","author":"Ngolab","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuron.2023.03.021_bib121","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal \u03b1-synuclein is likely CNS-derived and increased in Parkinson\u2019s disease","volume":"128","author":"Shi","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib122","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson\u2019s disease diagnosis: a systematic review and meta-analysis","volume":"125","author":"Gao","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.neuron.2023.03.021_bib123","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/brain\/awac115","article-title":"Detection of neuron-derived pathological \u03b1-synuclein in blood","volume":"145","author":"Kluge","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib124","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.biocel.2008.01.017","article-title":"Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein","volume":"40","author":"Lee","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.neuron.2023.03.021_bib125","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00401-016-1538-0","article-title":"Axonal transport and secretion of fibrillar forms of \u03b1-synuclein, A\u03b242 peptide and HTTExon 1","volume":"131","author":"Brahic","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib126","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.23747","article-title":"Neuron-to-neuron transmission of \u03b1-synuclein fibrils through axonal transport","volume":"72","author":"Freundt","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib127","doi-asserted-by":"crossref","first-page":"105696","DOI":"10.1016\/j.nbd.2022.105696","article-title":"Extracellular alpha-synuclein: sensors, receptors, and responses","volume":"168","author":"Domingues","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib128","doi-asserted-by":"crossref","first-page":"aah3374","DOI":"10.1126\/science.aah3374","article-title":"Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.neuron.2023.03.021_bib129","doi-asserted-by":"crossref","first-page":"e14745","DOI":"10.15252\/emmm.202114745","article-title":"LAG3 is not expressed in human and murine neurons and does not modulate \u03b1-synucleinopathies","volume":"13","author":"Emmenegger","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib130","doi-asserted-by":"crossref","first-page":"10050","DOI":"10.1038\/s41598-017-10236-x","article-title":"\u03b1-Synuclein amyloids hijack prion protein to gain cell entry, facilitate cell-to-cell spreading and block prion replication","volume":"7","author":"Auli\u0107","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuron.2023.03.021_bib131","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/nn.4648","article-title":"\u03b1-Synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B","volume":"20","author":"Ferreira","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuron.2023.03.021_bib132","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1038\/s41467-022-32625-1","article-title":"Lysosomal exocytosis releases pathogenic \u03b1-synuclein species from neurons in synucleinopathy models","volume":"13","author":"Xie","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuron.2023.03.021_bib133","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13024-019-0335-3","article-title":"Microglia affect \u03b1-synuclein cell-to-cell transfer in a mouse model of Parkinson\u2019s disease","volume":"14","author":"George","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuron.2023.03.021_bib134","doi-asserted-by":"crossref","first-page":"eabk0637","DOI":"10.1126\/science.abk0637","article-title":"GPNMB confers risk for Parkinson\u2019s disease through interaction with \u03b1-synuclein","volume":"377","author":"Diaz-Ortiz","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neuron.2023.03.021_bib135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm.2294","article-title":"Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion","volume":"17","author":"Atarashi","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib136","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/35081095","article-title":"Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding","volume":"411","author":"Saborio","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2023.03.021_bib137","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0166-2236(02)02195-1","article-title":"Cyclic amplification of protein misfolding: application to prion-related disorders and beyond","volume":"25","author":"Soto","year":"2002","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuron.2023.03.021_bib138","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib139","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib141","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.25824","article-title":"Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies","volume":"88","author":"Singer","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib142","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cell.2013.05.057","article-title":"Distinct \u03b1-synuclein strains differentially promote tau inclusions in neurons","volume":"154","author":"Guo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neuron.2023.03.021_bib143","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/ncomms3575","article-title":"Structural and functional characterization of two alpha-synuclein\u00a0strains","volume":"4","author":"Bousset","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuron.2023.03.021_bib144","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature14547","article-title":"\u03b1-Synuclein strains cause distinct synucleinopathies after local and systemic administration","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2023.03.021_bib145","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1074\/jbc.RA118.004471","article-title":"Parkinson\u2019s disease and multiple system atrophy have distinct \u03b1-synuclein seed characteristics","volume":"294","author":"Yamasaki","year":"2019","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuron.2023.03.021_bib146","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","article-title":"Structures of \u03b1-synuclein filaments from human brains with Lewy pathology","volume":"610","author":"Yang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2023.03.021_bib147","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nrm2204","article-title":"Insights into prion strains and neurotoxicity","volume":"8","author":"Aguzzi","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.neuron.2023.03.021_bib148","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1146\/annurev-pathmechdis-012418-013109","article-title":"Cellular and molecular mechanisms of prion disease","volume":"14","author":"Sigurdson","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib149","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuron.2023.03.021_bib150","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1038\/emm.2013.45","article-title":"Autophagic failure promotes the exocytosis and intercellular transfer of \u03b1-synuclein","volume":"45","author":"Lee","year":"2013","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib151","doi-asserted-by":"crossref","first-page":"18666","DOI":"10.1073\/pnas.1105725108","article-title":"\u03b1-Synuclein fate is determined by USP9X-regulated monoubiquitination","volume":"108","author":"Rott","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2023.03.021_bib152","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature05291","article-title":"The roles of intracellular protein-degradation pathways in neurodegeneration","volume":"443","author":"Rubinsztein","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2023.03.021_bib153","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1083\/jcb.201003122","article-title":"\u03b1-Synuclein impairs macroautophagy: implications for Parkinson\u2019s disease","volume":"190","author":"Winslow","year":"2010","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuron.2023.03.021_bib154","doi-asserted-by":"crossref","first-page":"12924","DOI":"10.1074\/jbc.M306390200","article-title":"Proteasomal inhibition by \u03b1-synuclein filaments and oligomers","volume":"279","author":"Lindersson","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuron.2023.03.021_bib155","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.nbd.2012.03.017","article-title":"Regional deficiencies in chaperone-mediated autophagy underlie \u03b1-synuclein aggregation and neurodegeneration","volume":"46","author":"Malkus","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib156","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.neuron.2023.03.021_bib157","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/brain\/awx285","article-title":"Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease","volume":"140","author":"Robak","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib158","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1212\/WNL.0b013e31828f180e","article-title":"The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease","volume":"80","author":"Gan-Or","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib159","doi-asserted-by":"crossref","first-page":"2890.e13-5","DOI":"10.1016\/j.neurobiolaging.2013.06.010","article-title":"Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson\u2019s disease","volume":"34","author":"Foo","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuron.2023.03.021_bib160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neuron.2023.03.021_bib161","doi-asserted-by":"crossref","first-page":"eaau6870","DOI":"10.1126\/scitranslmed.aau6870","article-title":"A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson\u2019s disease","volume":"11","author":"Burbulla","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib162","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.20321","article-title":"\u03b1-Synuclein pathology does not predict extrapyramidal symptoms or dementia","volume":"57","author":"Parkkinen","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib163","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00401-008-0345-7","article-title":"Evidence that incidental Lewy body disease is pre-symptomatic Parkinson\u2019s disease","volume":"115","author":"Dickson","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib164","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","article-title":"Neuropathology of cognitively normal elderly","volume":"62","author":"Knopman","year":"2003","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib165","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00401-005-0015-y","article-title":"Characteristics of alpha-synucleinopathy in centenarians","volume":"111","author":"Ding","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib166","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00401-008-0346-6","article-title":"Applicability of current staging\/categorization of \u03b1-synuclein pathology and their clinical relevance","volume":"115","author":"Parkkinen","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib167","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-008-0344-8","article-title":"The progression of pathology in longitudinally followed patients with Parkinson\u2019s disease","volume":"115","author":"Halliday","year":"2008","journal-title":"Acta Neuropathol."},{"issue":"Suppl 3","key":"10.1016\/j.neuron.2023.03.021_bib168","first-page":"270","article-title":"Formation and development of Lewy pathology: a critical update","volume":"256","author":"Jellinger","year":"2009","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib169","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","article-title":"Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction","volume":"117","author":"Beach","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib170","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/jnen\/64.2.156","article-title":"Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore longitudinal study of aging (BLSA)","volume":"64","author":"Mikolaenko","year":"2005","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib171","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2009.05118.x","article-title":"The progression of pathology in Parkinson\u2019s disease","volume":"1184","author":"Halliday","year":"2010","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.neuron.2023.03.021_bib172","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1212\/WNL.0b013e318278fe32","article-title":"Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease","volume":"79","author":"Milber","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib173","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00441-018-2854-6","article-title":"Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity?","volume":"373","author":"Chartier","year":"2018","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuron.2023.03.021_bib174","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00702-018-1898-9","article-title":"Is Braak staging valid for all types of Parkinson\u2019s disease?","volume":"126","author":"Jellinger","year":"2019","journal-title":"J.\u00a0Neural Transm. (Vienna)"},{"key":"10.1016\/j.neuron.2023.03.021_bib175","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2990.2008.00937.x","article-title":"The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson\u2019s disease","volume":"34","author":"Attems","year":"2008","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neuron.2023.03.021_bib176","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1212\/01.wnl.0000306697.48738.b6","article-title":"Patterns and stages of \u03b1-synucleinopathy","volume":"70","author":"Zaccai","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib177","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/mds.23305","article-title":"Brain stem pathology in Parkinson\u2019s disease: an evaluation of the Braak staging model","volume":"25","author":"Kingsbury","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib178","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuron.2023.03.021_bib179","first-page":"493","article-title":"Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson\u2019s disease","volume":"256","author":"Williams-Gray","year":"2009","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib180","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/mds.24946","article-title":"Genetic influences on cognitive decline in Parkinson\u2019s disease","volume":"27","author":"Morley","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib181","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaneurol.2014.1455","article-title":"APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease","volume":"71","author":"Mata","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib182","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/mds.27204","article-title":"APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson\u2019s disease","volume":"33","author":"Tropea","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib183","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e318253d54b","article-title":"Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study","volume":"78","author":"Alcalay","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib184","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mds.24045","article-title":"Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson\u2019s disease course","volume":"27","author":"Set\u00f3-Salvia","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib185","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/brain\/aws318","article-title":"Glucocerebrosidase mutations influence the natural history of Parkinson\u2019s disease in a community-based incident cohort","volume":"136","author":"Winder-Rhodes","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib186","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/jamaneurol.2013.1274","article-title":"Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations","volume":"70","author":"Chahine","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib187","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.26359","article-title":"GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson\u2019s disease","volume":"31","author":"Mata","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib188","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.10846","article-title":"Comparison of kindreds with parkinsonism and \u03b1-synuclein genomic multiplications","volume":"55","author":"Farrer","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib189","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41588-021-00847-6","article-title":"Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson\u2019s disease","volume":"53","author":"Liu","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuron.2023.03.021_bib190","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","article-title":"Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture","volume":"53","author":"Chia","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuron.2023.03.021_bib191","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00401-020-02199-7","article-title":"ADNC-RS, a clinical-genetic risk score, predicts Alzheimer\u2019s pathology in autopsy-confirmed Parkinson\u2019s disease and Dementia with Lewy bodies","volume":"140","author":"Dai","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.03.021_bib192","doi-asserted-by":"crossref","first-page":"e0147319","DOI":"10.1371\/journal.pone.0147319","article-title":"An Alzheimer\u2019s disease-derived biomarker signature identifies Parkinson\u2019s disease patients with dementia","volume":"11","author":"Berlyand","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neuron.2023.03.021_bib193","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mds.25846","article-title":"What can biomarkers tell us about cognition in Parkinson\u2019s disease?","volume":"29","author":"Mollenhauer","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib194","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neurobiolaging.2021.08.020","article-title":"Brain age and Alzheimer\u2019s-like atrophy are domain-specific predictors of cognitive impairment in Parkinson\u2019s disease","volume":"109","author":"Chariss\u00e9","year":"2022","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuron.2023.03.021_bib195","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/brain\/awr277","article-title":"Alzheimer\u2019s disease pattern of brain atrophy predicts cognitive decline in Parkinson\u2019s disease","volume":"135","author":"Weintraub","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.03.021_bib196","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.26191","article-title":"Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: a systematic review","volume":"30","author":"Petrou","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib197","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1212\/WNL.0000000000007855","article-title":"Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease","volume":"93","author":"Shirvan","year":"2019","journal-title":"Neurology"},{"issue":"Suppl","key":"10.1016\/j.neuron.2023.03.021_bib198","first-page":"S213","article-title":"The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk","volume":"10","author":"Tanner","year":"2014","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.neuron.2023.03.021_bib199","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005522","article-title":"Mild TBI and risk of Parkinson disease. A chronic effects of neurotrauma consortium study","volume":"90","author":"Gardner","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.03.021_bib200","doi-asserted-by":"crossref","first-page":"a009316","DOI":"10.1101\/cshperspect.a009316","article-title":"A guide to neurotoxic animal models of Parkinson\u2019s disease","volume":"1","author":"Tieu","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib201","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1007\/s12035-017-0830-x","article-title":"Trichloroethylene and Parkinson\u2019s disease: risk assessment","volume":"55","author":"Liu","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuron.2023.03.021_bib202","doi-asserted-by":"crossref","first-page":"134437","DOI":"10.1016\/j.neulet.2019.134437","article-title":"Trichloroethylene and its metabolite TaClo lead to degeneration of substantia nigra dopaminergic neurones: effects in wild type and human A30P mutant \u03b1-synuclein mice","volume":"711","author":"Keane","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuron.2023.03.021_bib203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.brainres.2017.03.002","article-title":"Moderate traumatic brain injury increases the vulnerability to neurotoxicity induced by systemic administration of 6-hydroxydopamine in mice","volume":"1663","author":"de Oliveira","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.neuron.2023.03.021_bib204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease epidemiology, pathology, genetics, and pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib205","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2016.1948","article-title":"Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings","volume":"73","author":"Crane","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib206","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12028-013-9933-z","article-title":"Differential disruption of blood\u2013brain barrier in severe traumatic brain injury","volume":"20","author":"Saw","year":"2014","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.neuron.2023.03.021_bib207","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.injury.2007.10.005","article-title":"Modulation of immune response by head injury","volume":"38","author":"Morganti-Kossmann","year":"2007","journal-title":"Injury"},{"key":"10.1016\/j.neuron.2023.03.021_bib208","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12035-022-03094-w","article-title":"Role of TREM2 in the development of neurodegenerative diseases after traumatic brain injury","volume":"60","author":"Zhang","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuron.2023.03.021_bib209","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.28551","article-title":"Type 2 diabetes as a determinant of Parkinson\u2019s disease risk and progression","volume":"36","author":"Chohan","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2023.03.021_bib210","doi-asserted-by":"crossref","first-page":"105698","DOI":"10.1016\/j.nbd.2022.105698","article-title":"Inflammation in dementia with Lewy bodies","volume":"168","author":"Amin","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2023.03.021_bib211","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.arr.2018.05.004","article-title":"Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: a systematic review and meta-analysis","volume":"46","author":"Custodero","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuron.2023.03.021_bib212","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ana.26410","article-title":"Plasma MIA, CRP, and albumin predict cognitive decline in Parkinson\u2019s disease","volume":"92","author":"Shen","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.03.021_bib213","doi-asserted-by":"crossref","first-page":"eaay3069","DOI":"10.1126\/scitranslmed.aay3069","article-title":"APOE genotype regulates pathology and disease progression in synucleinopathy","volume":"12","author":"Davis","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib214","doi-asserted-by":"crossref","first-page":"eaay1809","DOI":"10.1126\/scitranslmed.aay1809","article-title":"APOE4 exacerbates \u03b1-synuclein pathology and related toxicity independent of amyloid","volume":"12","author":"Zhao","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuron.2023.03.021_bib215","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2015.08.002","article-title":"TMEM175 is an organelle K+ channel regulating lysosomal function","volume":"162","author":"Cang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.neuron.2023.03.021_bib216","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41586-021-03185-z","article-title":"A growth-factor-activated lysosomal K+ channel regulates Parkinson\u2019s pathology","volume":"591","author":"Wie","year":"2021","journal-title":"Nature"}],"container-title":["Neuron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627323002179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627323002179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:20:29Z","timestamp":1762316429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896627323002179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":216,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0896627323002179"],"URL":"https:\/\/doi.org\/10.1016\/j.neuron.2023.03.021","relation":{},"ISSN":["0896-6273"],"issn-type":[{"value":"0896-6273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive heterogeneity in Parkinson\u2019s disease: A mechanistic view","name":"articletitle","label":"Article Title"},{"value":"Neuron","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuron.2023.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}